When should SBRT be offered to oligometastatic bone disease in a patient with prostate cancer?

Recently a multi-institutional analysis set standards for use in prospective assessment of SBRT for use in men with > 1 bone metastasis and up to 3 (data shown below). The Rx was well tolerated and local control was significantly improved if a BED > 100 Gy was utilized.

At this time this approach re...

SBRT for prostate cancer in the asymptomatic setting in order to improve survival or progression-free survival should be considered an unproven but potentially useful approach. Note that NRG Oncology-RTOG is testing SBRT prospectively.

Trial BR001 is a phase I trial assessing the safety of SBRT for...